Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

These researchers from McGill University are using waste could potentially expand how and where low-carbon hydrogen can be ...

"These findings suggest that consciously generated positive expectations can engage reward circuitry to influence immune ...

Businesses play a critical role in building a new, integrated system of learning and work because they see change first. They ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Reinventy Solutions Corp. announced an advance in its materials-driven technology roadmap, highlighting XHT™ (eXtended High-Temperature) material architectures and Phantom Core™ electric system ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...